序贯使用XPO1与ATR抑制剂增强TP53突变结直肠癌治疗反应
该研究通过患者来源异种移植(PDX)的功能基因组学与高通量药物筛选,发现XPO1抑制剂可诱导结直肠癌(CRC)DNA损伤致死。在TP53突变CRC中,XPO1抑制激活ATM/ATR-CHK1/2轴导致适应性耐药,序贯KPT-8602后AZD-6738可产生显著抗肿瘤效应并延长生存。
要点
- XPO1抑制剂在CRC中驱动DNA损伤诱导的细胞死亡。
- TP53突变CRC经XPO1抑制后激活ATM/ATR-CHK1/2轴产生适应。
- 序贯XPO1抑制剂后ATR抑制剂可增强TP53突变CRC疗效。
核心结论
- XPO1抑制剂尤其与DNA损伤检查点抑制剂联合,可能为携带TP53突变的CRC患者带来持久临床获益。
研究设计与样本
- 研究采用患者为中心的功能基因组学平台,涵盖约200个基因。
- 在高通量药物筛选中使用262种化合物,于4例CRC患者来源异种移植(PDX)中筛选。
主要发现
- 两种筛选方法均将exportin 1(XPO1)抑制剂鉴定为CRC中DNA损伤诱导致死性的驱动因素。
- XPO1抑制后的适应性机制限制了TP53突变CRC模型的反应持续时间,而TP53野生型模型未见此现象。
- TP53突变CRC细胞在XPO1抑制剂处理后选择性激活ATM/ATR-CHK1/2轴,该反应为适应治疗和逃避细胞死亡所需。
- 序贯给予KPT-8602(XPO1抑制剂)后AZD-6738(ATR抑制剂)在TP53突变CRC模型中产生显著抗肿瘤效应并延长生存。
临床怎么用
- 对TP53突变CRC可考虑XPO1抑制剂序贯ATR抑制剂的联合策略。
- 治疗中需关注XPO1抑制后ATM/ATR-CHK1/2轴激活介导的适应性耐药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Understanding the mechanisms by which tumors adapt to therapy is critical for developing effective combination therapeutic approaches to improve clinical outcomes for patients with cancer. METHODS: To identify promising and clinically actionable targets for managing colorectal cancer (CRC), we conducted a patient-centered functional genomics platform that includes approximately 200 genes and paired this with a high-throughput drug screen that includes 262 compounds in four patient-derived xenografts (PDXs) from patients with CRC. RESULTS: Both screening methods identified exportin 1 (XPO1) inhibitors as drivers of DNA damage-induced lethality in CRC. Molecular characterization of the cellular response to XPO1 inhibition uncovered an adaptive mechanism that limited the duration of response in TP53-mutated, but not in TP53-wild-type CRC models. Comprehensive proteomic and transcriptomic characterization revealed that the ATM/ATR-CHK1/2 axes were selectively engaged in TP53-mutant CRC cells upon XPO1 inhibitor treatment and that this response was required for adapting to therapy and escaping cell death. Administration of KPT-8602, an XPO1 inhibitor, followed by AZD-6738, an ATR inhibitor, resulted in dramatic antitumor effects and prolonged survival in TP53-mutant models of CRC. CONCLUSIONS: Our findings anticipate tremendous therapeutic benefit and support the further evaluation of XPO1 inhibitors, especially in combination with DNA damage checkpoint inhibitors, to elicit an enduring clinical response in patients with CRC harboring TP53 mutations.
引用
- Inoue A, Robinson FS, Minelli R, et al. Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer. Gastroenterology. 2021. PMID: 33745946. doi:10.1053/j.gastro.2021.03.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。